Skip to main content

Bone Biologics Corp

BBLG
Exchange
Nasdaq
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
SEC CIK
0001419554

No open-market purchases or sales by Bone Biologics Corp insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q3 2026, worth $215.1K in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 27, 2026, 1:07 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Bone Biologics Corp, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported–––––
Operating expenses$3.23M$4.22M$9.43M$3.67M$1.10M
Research and development$1.06M$2.13M$6.91M$1.58M$82.0K
Selling, general and administrative$2.17M$2.09M$2.52M$2.09M$1.02M
Operating income-$3.23M-$4.22M-$9.43M-$3.67M-$1.10M
Income tax––––$1.60K
Net income-$3.11M-$4.11M-$8.95M-$1.48M-$1.61M
EPS, basic$-2.65$-4.83$-34.01$-0.13–
EPS, diluted$-2.65$-4.83$-34.01––
Weighted shares, basic1.17M1.52M263.1K––
Weighted shares, diluted1.17M1.52M263.1K––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Bone Biologics Corp, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported–––––
Cash and equivalents$5.33M$3.33M$3.03M$7.54M$6.68M
Total current assets$5.80M$3.86M$3.74M––
Total assets$5.80M$3.86M$3.74M$8.50M$6.68M
Total current liabilities$418.6K$377.7K$831.4K$2.55M–
Total liabilities$418.6K$377.7K$831.4K$2.55M$99.9K
Shareholders' equity$5.38M$3.48M$2.91M$5.95M$6.58M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Bone Biologics Corp, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported–––––
Operating cash flow-$2.69M-$4.12M-$9.56M-$3.57M-$1.23M
Stock-based compensation$256.4K$188.8K$152.6K$266.6K$207.0K
Financing cash flow$4.70M$4.42M$5.04M$4.43M$7.90M
Net change in cash$2.01M$298.6K-$4.51M$862.9K$6.68M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Bone Biologics Corp by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 26, 20263.39M+88.8%SEC
Aug 14, 20262.76M+53.5%SEC
May 14, 20261.80M−45.1%SEC
Feb 23, 20261.80M−45.1%SEC
Nov 14, 20251.80M−27.1%SEC
Aug 14, 20251.80M−0.3%SEC
May 1, 20253.27M+197.2%SEC
Feb 19, 20253.27M+512.3%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.